Wednesday, May 23, 2012 2:45:21 PM
k you can look at it two ways. One a buyout didn't happen an they just shut down the business. (WHICH MAKES ABSOLUTELY NO SENSE TO ME WKTH LESSS THEN 3.5 MILLION IN DEBT COMPARED TO 26+ MILLION IN REVENUES.
OR TWO, the company is winding down After finishing negotiations UNTIL we can close the deal. THE PR WAS WORDED SO VAGUELY SO THEY CAN GET THIS EXACT RESPONSE FROM US.
HAS ANYONE ASKED WHY ATRN IS RAISING EQUITY THROUGH AN INVESTMENT BANK?! BUYIN BACK THE OS TO GO PRIVATE? EXPENDING INTO LARGER MARKET?!
Dont be suckered in.
OR TWO, the company is winding down After finishing negotiations UNTIL we can close the deal. THE PR WAS WORDED SO VAGUELY SO THEY CAN GET THIS EXACT RESPONSE FROM US.
HAS ANYONE ASKED WHY ATRN IS RAISING EQUITY THROUGH AN INVESTMENT BANK?! BUYIN BACK THE OS TO GO PRIVATE? EXPENDING INTO LARGER MARKET?!
Dont be suckered in.
Recent PTIX News
- Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114 • ACCESS Newswire • 03/17/2026 12:00:00 PM
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market • ACCESS Newswire • 03/10/2026 12:00:00 PM
- Results from Phase 1 Multiple-Dose Study of PT00114 • ACCESS Newswire • 12/09/2025 01:46:00 PM
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice • ACCESS Newswire • 11/27/2025 08:45:00 AM
- Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study • ACCESS Newswire • 11/13/2025 01:22:00 PM
- Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates • GlobeNewswire Inc. • 07/30/2025 12:30:00 PM
